Rituximab

Rituximab is a monoclonal antibody used for the treatment of certain autoimmune and blood-related conditions. It is a targeted therapy designed to attack specific cells in the body, known as B cells, which are involved in the immune response. By inhibiting the growth and activity of these B cells, rituximab can help to alleviate symptoms and manage the progression of specific diseases.
One of the primary uses of rituximab is in the treatment of non-Hodgkin’s lymphoma (NHL), a type of cancer that affects the lymphatic system. Rituximab is often administered in combination with other chemotherapy drugs to target and destroy cancerous B cells. It is also used as a standalone therapy for patients with relapsed or refractory NHL who have not responded well to other treatments.
In addition to its application in oncology, rituximab is used to treat autoimmune diseases such as rheumatoid arthritis and granulomatosis with polyangiitis (GPA). In these cases, rituximab works by reducing the inflammatory response and preventing the overactive immune system from causing damage to the body’s tissues.
Before starting treatment with rituximab, consult with a healthcare professional to determine the most suitable course of action based on the individual’s specific condition and medical history.